These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32429656)

  • 1. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
    Stolnicu S; Tunde C; Cadar A; Boros M
    Pol J Pathol; 2020; 71(1):62-65. PubMed ID: 32429656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
    Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
    Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].
    Sun XJ; Zuo K; Tang SX; Lu HF; Shui RH; Yu BH; Xu XL; Cheng YF; Tu XY; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2017 Jul; 46(7):476-480. PubMed ID: 28728221
    [No Abstract]   [Full Text] [Related]  

  • 5. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
    Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
    Braxton DR; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
    Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
    Law T; Piotrowski MJ; Ning J; Jiang X; Ding Q; Sahin AA
    Hum Pathol; 2023 Aug; 138():62-67. PubMed ID: 37331526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
    Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
    Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
    Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
    Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.
    Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM
    Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
    El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
    Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer.
    Husni Cangara M; Miskad UA; Masadah R; Nelwan BJ; Wahid S
    Breast Dis; 2021; 40(S1):S27-S31. PubMed ID: 34057115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
    Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
    BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.